top stories

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

17 hours ago
Law

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

16 hours ago
R&D
FDA+

JP­M's M&A Mon­day fren­zy; Ozem­pic se­lect­ed for IRA ne­go­ti­a­tions; Pfiz­er says it's back on track; and more

1 hour ago
Weekly

Latest

Most read

Up­dat­ed: J&J to buy In­tra-Cel­lu­lar for $14.6B in lat­est neu­ro­science bet

4 days ago
Deals

Sage sues Bio­gen days af­ter $469M buy­out of­fer

14 hours ago
Pharma
Law

WuXi AppTec sells med­ical de­vice test­ing unit; Lay­offs at Notch Ther­a­peu­tics

20 hours ago
News Briefing

No­vo claims high-dose Phase 3 We­govy win but sales im­pact might be mut­ed

20 hours ago
R&D
Pharma
see latest stream
People

De­part­ing FDA com­mis­sion­er: 'We're los­ing the bat­tle on mis­in­for­ma­tion'

Yesterday

Lykos up­heaval con­tin­ues with four new board ex­its amid hunt for cash

3 days ago

Ex­clu­sive: Day af­ter GSK buy­out, IDRx chair takes new in­vest­ing role at Curie.Bio

3 days ago
Financing

Sh­iono­gi lands $375M from HHS to de­vel­op pre­ven­tive drug for Covid-19

Yesterday

Vac­cine patch start­up col­lects an ad­di­tion­al $16M to Se­ries A

2 days ago

Umo­ja’s $100M Se­ries C will ad­vance its bid for more con­ve­nient cell ther­a­pies

3 days ago
Startups

Nor­mu­ni­ty nabs $75M Se­ries B to ad­vance T cell en­gager and launch first tri­al

4 days ago

Lil­ly to ac­quire can­cer biotech Scor­pi­on, which shares a co-founder with Loxo

4 days ago

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

Last week
Deals

A mixed year for deals and dol­lars left biotech ex­ecs hun­gry for a bet­ter 2025

2 days ago

Re­genxbio sells Hunter syn­drome li­cense with FDA fil­ing un­der­way

3 days ago

Aus­trali­a's BioCi­na and No­vaCi­na join forces to make one CD­MO

3 days ago

In FocusSee all

Broad In­sti­tute pa­per of­fers po­ten­tial new frame­work for treat­ing Hunt­ing­ton’s dis­ease

Yesterday
R&D

How a du­ty to spend wise­ly on work­er ben­e­fits could loosen PBM­s' grip on drug prices

Last month
Pharma
Law

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

Last month
AI

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

Last month
R&D
Discovery

Endpoints Standouts

How the world's biggest phar­ma and biotech com­pa­nies paid their typ­i­cal work­er in 2023

6 months ago
People
Pharma

In biotech's un­even re­cov­ery, 50 star­tups raised megarounds in first half of 2024

6 months ago
Financing
Startups

Bio­phar­ma lead­ers chart­ing a path for the in­dus­try's LGBTQ+ com­mu­ni­ty

6 months ago
People
Special

Pe­ter Marks sin­gle-hand­ed­ly ap­proved Sarep­ta’s gene ther­a­py — what does that mean for every­one else?

7 months ago
Pharma
Cell/Gene Tx

Peer review See all

Jan
17

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

Jan
10

John Maraganore turns to ex-Al­ny­lam col­league to lead his lat­est RNAi bet; Amy­lyx names com­mer­cial chief

Dec
20

Dai­ichi Sankyo finds suc­ces­sor to late R&D ex­ec; Ver­sant, No­var­tis' kid­ney biotech poach­es Sana CBO

Dec
13

Xaira hires for­mer Roche ex­ec as CMO; 'Tis the sea­son for re­tire­ments at Al­ny­lam, Re­gen­eron

Dec
6

Mark Alles’ ADC bet TORL poach­es J&J med­ical ex­ec; Sam­sung Bioepis makes his­toric CEO ap­point­ment

Pharma channel feed

22 hours ago

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

No­vo Nordisk’s block­buster GLP-1 prod­ucts Ozem­pic and We­govy are among the next 15 drugs sub­ject to the gov­ern­ment’s Medicare ne­go­ti­a­tion pro­gram un­der the In­fla­tion Re­duc­tion Act, ...

READ MORE

Af­ter three-month de­lay, Am­gen’s Lumakras clinch­es FDA green light in col­orec­tal can­cer

Yesterday

Roche's car­diometa­bol­ic chief warns against weight loss 'ob­ses­sion' with GLP-1s

Yesterday
latest in Pharma

Te­va says it has a 'u­nique po­si­tion' in lat­est IRA chal­lenge

Yesterday
Law

HHS blasts Boehringer's drug price case, re­veals new de­tails on Jar­diance talks

Yesterday
Law

EMA in 2024 rec­om­mend­ed high­est num­ber of drug ap­provals in 15 years

Yesterday

No­var­tis en­ters fight against HHS for deny­ing its 340B re­bate mod­el

Yesterday
Law

Eli Lil­ly's Omvoh earns FDA ap­proval for Crohn's dis­ease

2 days ago
FDA+
see latest stories

Marketing channel feed

Last week

J&J's new can­cer com­bo beats As­traZeneca's Tagris­so on sur­vival in lung tri­al

John­son & John­son said its re­cent­ly ap­proved Ry­bre­vant and Laz­cluze com­bi­na­tion ther­a­py topped Tagris­so on over­all sur­vival in a Phase 3 tri­al, notch­ing a key win in its ri­val­ry against ...

READ MORE

Drugs are ap­proved — and made avail­able — faster in US than most of EU, da­ta show

Last month
Pharma
FDA+

No­var­tis bol­sters Fab­hal­ta da­ta in com­pe­ti­tion with As­traZeneca

Last month
R&D
latest in Marketing

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Last month
Pharma

FDA says Merz's so­cial me­dia pro­mo­tion with Nate Berkus is 'mis­lead­ing'

2 months ago
Pharma

Val­ne­va and Pfiz­er eye 2027 launch for part­nered Ly­me dis­ease vac­cine

3 months ago
Pharma

UK watch­dog crit­i­cizes Mod­er­na for Covid-19 tri­al's use of What­sApp to dan­gle pay­ments to chil­dren

3 months ago
Pharma

FDA crit­i­cizes Ab­b­Vie's 'mis­lead­ing' ad with Ser­e­na Williams

4 months ago
Pharma
FDA+
see latest stories

FDA+ channel feed

Yesterday

FDA re­jects Atara's cell ther­a­py for rare trans­plant com­pli­ca­tion, stock craters

US reg­u­la­tors have re­ject­ed a T cell ther­a­py for a rare and se­ri­ous trans­plant com­pli­ca­tion re­lat­ed to Ep­stein-Barr virus from Atara Bio­ther­a­peu­tics and Pierre Fab­re.

READ MORE

FDA ex­plains why it re­ject­ed Van­da's stom­ach drug in late 2024

2 days ago

HHS in­spec­tor gen­er­al rais­es con­cerns over three FDA ac­cel­er­at­ed ap­provals

3 days ago
latest in FDA+

BIO CEO plans to join FDA mod­ern­iza­tion ad­vi­so­ry board un­der Trump ad­min­is­tra­tion

4 days ago

FDA ad­comm votes to sup­port Seik­a­gaku's her­ni­at­ed disc in­jec­tion

Last week
Pharma

Pfiz­er touts blad­der can­cer re­sults as first ad­vance­ment for some pa­tients 'in decades'

Last week
R&D
Pharma

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

Last week
People

Bay­er says elin­zane­tant quelled hot flash­es in women un­der­go­ing can­cer treat­ment

Last week
R&D
Pharma
see latest stories

Manufacturing channel feed

Yesterday

Den­mark’s new man­u­fac­tur­ing learn­ing cen­ter; Telix buys fa­cil­i­ty, as­sets and tech from Imag­inAb

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more.

READ MORE

Sam­sung Bio eyes con­struc­tion of sixth man­u­fac­tur­ing plant to kick­start 2025

2 days ago

Eli Lil­ly miss­es 2024 rev­enue ex­pec­ta­tions, stock dips 7%

3 days ago
Pharma
latest in Manufacturing

Charles Riv­er dis­ap­points in­vestors with damp out­look for 2025

3 days ago

Ara­gen gets $100M from pri­vate eq­ui­ty firm to ex­pand man­u­fac­tur­ing foot­print 

4 days ago
Financing

As­traZeneca, CRISPR tools sup­pli­er ink gene edit­ing en­zyme li­cens­ing deal

4 days ago
Deals

Sam­sung Bio ex­tends ADC part­ner­ship; Vee­da re­brands as CD­MO

Last week

Synaf­fix adds Boehringer and Mit­subishi Tan­abe as ADC li­cens­ing part­ners

Last week
Deals
see latest stories
A service from the Financial Times